flâneur

RNA Interference–Based Therapy and Its Delivery Systems - PMC

ncbi.nlm.nih.gov · 8,400 words · saved by 1 readers

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China 1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3Center for RNA Interference and Non-Coding

. Author manuscript; available in PMC: 2019 Mar 1. Published in final edited form as: Cancer Metastasis Rev. 2018 Mar;37(1):107–124. doi: 10.1007/s10555-017-9717-6 Abstract RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful…

saved by

related reading